Edit
Fluidx Medical Technology, Inc.
https://www.fluidxmedical.com/Last activity: 06.08.2026
Active
The GPX and IMPASS Embolic Device platforms are under development and do not have marketing clearance or approval in any market at this time.
Location: United States, Utah, Salt Lake City
Employees: 11-50
Investors 1
| Date | Name | Website |
| - | MedMountai... | mmv.vc |
Mentions in press and media 10
| Date | Title | Description |
| 06.08.2026 | Fluidx Medical Closes Financing to Advance Next-Generation Embolic Platform | Investment will support commercialization of GPX and ULTRA Embolic Devices and development of IMPASS neurovascular platform. This financing is an important milestone for Fluidx as we continue executing on our mission to redefine embolizatio... |
| 24.07.2026 | Fluidx Completes Submission of Premarket Approval Application for the GPX® Embolic Device | Final module of PMA application submitted to FDA for easy to use, controllable embolic Completing the PMA submission for GPX is a significant milestone towards our mission to bring to market a new category of easy to use, controllable embol... |
| 14.07.2026 | GPX® Embolic Device meets Primary Endpoints in an Investigational Device Exemption (IDE) Pivotal Trial | Trial Reports 99% Successful Occlusion of Flow with 40 Investigators Delivering the New Embolic Through 20 Different Catheters These results are impressive and should help establish GPX as an important new tool in embolic therapy once appro... |
| 02.07.2026 | Fluidx Announces Continued Clinical Success with ULTRA Embolic Gel | The ULTRA Embolic Device is designed for use in embolization of tumors and peripheral vascular hemorrhage. Novel gel embolic designed to give physicians greater control and consistency during embolization When further embolization is necess... |
| 02.04.2026 | Fluidx Medical Announces First Patient Treated with Novel Embolic Gel | The ULTRA Embolic Device is designed for use in embolization of tumors and peripheral vascular hemorrhage. Gel embolic device designed to simplify the embolization procedure and reduce risks to the patient. We could see the material very we... |
| 10.02.2026 | Fluidx IDE Trial Results Accepted for Late-Breaking Presentation at the SIR Annual Meeting | First podium presentation of IDE Clinical Trial Data of Novel Embolic Device to Treat Cancer The SIR clinical community will be key users of our next-gen gel embolic materials and we are excited that the first podium presentation will be at... |
| 07.01.2026 | IDE Pivotal Trial for Novel Liquid Embolic Device Completes Enrollment | Enrollment completed across 18 clinical sites with 40+ investigators in the US, Canada, and New Zealand If the GPX trial can confirm the positive results of the earlier study published in JVIR, it could help establish GPX as an important ne... |
| 27.11.2024 | Fluidx Medical Announces First Tumor Patient Treated in Prospective, Multinational Trial | The GPX Embolic Device is designed to occlude tumors and other distal applications Embolic device designed for improved preparation, delivery, and deep vessel filling for treating tumors and other interventional oncology uses. We are please... |
| 21.05.2024 | New Embolic Device for Tumor Treatment and Other Oncology Uses Given Nod by FDA to Start Pivotal Clinical Trial | Post-embolization angiogram of the GPX Embolic Device filling a pelvic tumor (as featured on the cover of Journal of Vascular and Interventional Radiology, February 2024) Investigators look forward to evaluating the new device designed for ... |
| 23.04.2021 | Christopher Phillips Named Chair of the BioUtah Regulatory, Compliance and Quality Committee | BioUtah today announced that Christopher Phillips, director of regulatory affairs and clinical affairs at Fluidx Medical Technology, has been appointed chair of BioUtah’s Regulatory, Compliance and Quality Committee. Phillips takes the rein... |